雷珠单抗联合视网膜光凝治疗缺血型视网膜静脉阻塞的临床研究

摘要/Abstract

摘要： 目的：探讨视网膜光凝术和视网膜光凝联合雷珠单抗玻璃体腔注药治疗缺血型视网膜静脉阻塞（RVO）的疗效差异。方法：选取我院缺血型RVO 60例（60眼）的临床资料进行临床对照研究。30眼视网膜中央静脉阻塞（CRVO）中，15眼行视网膜光凝术（A1组），15眼行视网膜光凝+雷珠单抗玻璃体腔注射（B1组）；30眼视网膜分支静脉阻塞(BRVO)中，15眼行视网膜光凝术（A2组），15眼行视网膜光凝+雷珠单抗玻璃体腔注射（B2组）。随诊12个月以上，对比治疗前后最佳矫正视力（BCVA）改善情况和新生血管消退率。结果： CRVO组治疗后BCVA改善差异有统计学意义（P<0.05），A1和B1组术前视力差异无统计学意义（P>0.05），术后不同时间点两组之间差异均有统计学意义（P<0.05）；BRVO组治疗后BCVA改善差异有统计学意义（P<0.05），A2和B2组术前视力差异无统计学意义（P>0.05），术后不同时间点差异均有统计学意义（P<0.05）。随访12个月， A组新生血管消退24眼（80%），B组新生血管消退30眼（100%），差异有统计学意义（P<0.05）。结论：对于缺血型RVO患者，雷珠单抗联合视网膜光凝组在新生血管消退率及BCVA提高上优于视网膜光凝组，雷珠单抗联合视网膜光凝组在激光治疗次数上少于视网膜光凝组。

关键词: font-size:medium, ">缺血型视网膜静脉阻塞；雷珠单抗；视网膜光凝；视网膜新生血管

Abstract: Objective： To investigate the effects of retinal photocoagulation and retinal photocoagulation combined with ranibizumab intravitreal injection on ischemic retinal vein occlusion(RVO). Methods： The clinical data of central retinal vein occlusion (CRVO) 30 eyes and branch retinal vein occlusion (BRVO) 30 eyes were compared. 15 eyes with CRVO underwent retinal photocoagulation (group A1)， and the remaining 15 eyes underwent retinal photocoagulation combined with ranibizumab intravitreal injection (group B1). 15 eyes with BRVO underwent retinal photocoagulation (group A2)， and the remaining 15 eyes underwent retinal photocoagulation combined with ranibizumab intravitreal injection (group B2). The regression rate of neovascularization of RVO and the improvement of BCVA before and after operation were compared and analyzed. Results： There were statistical differences（P<0.05） in BCVA before and after operation in group CRVO. There was no statistical difference（P>0.05） in preoperative BCVA between group A1 and B1， and there were statistical differences（P<0.05） in postoperative BCVA between group A1 and B1 at 1， 3， 6， and 12 months after operation. There were statistical significant differences（P<0.05） in BCVA before and after operation in group BRVO. There was no statistical difference（P>0.05） in preoperative BCVA between group A2 and B2， and there were statistical differences in postoperative BCVA between group A2 and B2 at 1， 3， 6， and 12 months after operation. There was statistical difference（P<0.05） in retinal neovascularization regression rate between group A(80%) and group B(100%). Conclusion： For ischemic RVO， the regression rate of neovascularization and BCVA improvement of retinal photocoagulation combined with ranibizumab intravitreal injection group were better than those of retinal photocoagulation group. The number of laser treatments in the ranibizumab combined retinal photocoagulation group was less than that of the retinal photocoagulation group.

Key words: font-size:medium, ">Ischemic retinal vein occlusion； Ranibizumab； Retinal photocoagulation； Retinal neovascularization

中图分类号:

邓瑾, 雷晓琴, 艾华, 孙文涛, 柴芳, 刘蓓. 雷珠单抗联合视网膜光凝治疗缺血型视网膜静脉阻塞的临床研究[J]. 中国医药导刊, 2020, 22(7): 460-464.

DENG Jin, LEI Xiaoqin, AI Hua, SUN Wentao, CHAI Fang, LIU Bei. Clinical Study on Ranibizumab Combined with Reinal Photocoagulation in the Treatment of Ischemic Retinal Vein Occlusion[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2020, 22(7): 460-464.

参考文献

参考文献
     [1]Rogers S， Mcintosh R， Lim L， et al. Natural history of branch retinal vein occlusion：an evidence-based systematic review[J]. Ophthalmology，2010，117(6)：1194-1101.
     [2]Hayreh SS， Podhajsky PA， Zimmerman MB . Natural history of visual outcome in central retinal vein occlusion[J]. Ophthalmology，2011，118(1)：119-133.
     [3]Pielen A， Mirshahi A， Feltgen N， et al. Ranibizumab for branch retinal vein occlusion associated macular edema study(RABAMES)：six-month results of a prospective randomized clinical trial[J]. Acta Ophthalmol，2015，93(1)：e29-e37.
     [4]张惠蓉.视网膜静脉阻塞分型探讨[J]. 中华眼科杂志，1998，34（3）：233-234.
     [5]张超，唐红，高纬，等.视网膜静脉阻塞发病的相关因素分析[J]. 陕西医学杂志， 2014，44（6）：696-699.
     [6]Hayreh SS， Zimmerman MB. Fundus changes in central retinal vein occlusion[J]. Retina，2015，35(5)：29-42.
     [7]陶相宜，郭淑玲，乔志艳，等.激光光凝对视网膜颞上分支静脉阻塞视网膜功能影响定量研究[J]. 中国实用眼科杂志，2013，31(12)：1562-1565.
     [8]Zcharia G， Bhat VK， Joseph MK， et al. Laser therapy in diabetic macular edema[J]. Oman Med J， 2008，23(1)：28-31.
     [9]张菁，蔡小军，陈晓敏，等.玻璃体腔注射康柏西普联合视网膜激光光凝治疗视网膜分支静脉阻塞继发黄斑水肿疗效观察[J]. 中华眼底病杂志， 2015， 31(1)：22- 26.
     [10]Karia N.Retinal vein occlusion：pathophysiololgy and treatment options[J]. Clin Ophthalmol，2010，(4)：809-816.
     [11]Noma H，Funatsu H，Mimura T， et al. Role of soluble vascular endothelial growth factor receptor-2 in macular edema with central retinal vein occlusion[J]. Br J Ophthalmol， 2011， 95(6)：788-792.
     [12]Noma H，Mimura T，Yasuda K， et al. Role of soluble vascular endothelial growth factor receptor signaling and other factors or cytokines in central retinal vein occlusion with macular edema[J]. Invest Ophthalmol Vis Sc， 2015， 56(2)：1122-1128.
     [13]Hufendiek K， Hufendiek K， Panagakis G， et al. Visual and morphological outcomes of bevacizumab(Avastin) versus anibizumab(Lucentis) treatmeng for retinal angiomatous proliferation[J]. Int Ophthalmol， 2012，32(3)：259-268.
     [14]许畅，黎智. 视网膜中央静脉阻塞伴发黄斑水肿患者房水中sCD200、VEGF表达[J]. 临床眼科杂志，2017，25(6)：488-493.
     [15]Pielen A， Mirshahi A， Feltgen N， et al. Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES)：six-month results of a prospective randomized clinical trial[J]. Acta Ophthalmol，2015，93(1)：e29-37.
     [16]Pece A， Isola V， Piermarocchi S， et al. Efficacy and safety of anti-vascular endothelial growth factor (VEGF)therapy with intravitreal ranibizumab (Lucentis)for nave retinal vein occlusion：1-year follow up[J]. Br J Ophthalmol，2011，95(1)：56-68.
     [17]李海辉，王彦荣，顾莉莉，等.应用频域OCT观察雷珠单抗注射液治疗视网膜静脉阻塞性黄斑水肿的疗效[J]. 陕西医学杂志，2016，45（12）：1693.
     [18]刘益帆，刘冬瑞，徐进，等.玻璃体注射雷珠单抗治疗老年性黄斑变性黄斑水肿与视网膜静脉阻塞性黄斑水肿的短期疗效观察[J]. 眼科，2017，26(2)：120-124.
     [19]宋艳，蒋晨.雷珠单抗玻璃体内注射联合氩激光视网膜光凝治疗缺血型视网膜中央静脉阻塞及其并发症78例[J]. 中国药业，2014，23(13)：84-85.
     [20]陆慧琴，武炳慧，吴惠琴. 玻璃体腔注射康柏西普治疗视网膜静脉阻塞并黄斑水肿[J]. 国际眼科杂志，2016，16(12)：2264-2267.
     [21]郝雪莲.血府逐瘀汤治疗视网膜静脉阻塞疗效观察[J]. 陕西中医，2017，38（7）：936-937.
     [22]李仕永，高瑞莹，陈晖. 雷珠单抗联合氩激光视网膜光凝治疗不同时期的视网膜分支静脉阻塞所致黄斑水肿的疗效[J]. 眼科新进展，2016，36(12)：1161-1164.

快速检索引用检索图表检索高级检索